All Resources

Leading T1D experts discuss scaling up screening programs to support equitable access to early T1D detection, monitoring, and disease-modifying therapies.  

Leading T1D experts discuss supportive care pathways, psychosocial support, and new models of care for people at risk of, or diagnosed with, type 1 diabetes.  

Experts discuss how to effectively communicate the value of T1D screening and early detection to families, clinicians, and healthcare decision-makers.   

Leading T1D experts explore how to distinguish adult-onset T1D from T2D and when to consider islet autoantibody testing in adults.  

In this panel Prof. Chantal Mathieu facilitated the discussion with Prof. Ezio Bonifacio, Prof. Thomas Kay, and Prof. John Wentworth. The speakers discussed biomarker-driven type 1 diabetes care, focusing on screening, diagnosis, and monitoring using autoantibodies, C-peptide, and glucose metrics. The panel highlighted the importance of early detection and risk stratification, reviewed immune-targeted therapies and emerging technologies, and emphasized key decision points supporting personalized, biomarker-guided T1D management. 

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.

Profs. Kay and Bonifacio discuss the role of T-cell dysregulation as a central pathophysiological mechanism in T1D, and its implications for emerging therapies and biomarkers

Prof Bonifacio discusses the predictive value and utility of islet autoantibodies as biomarkers of the risk and rate of progression to clinical T1D 

Prof. Wentworth discusses how T1D risk prediction can be improved through the development of tools that integrate multiple risk factors and biomarkers 

In this panel Prof. Alice Cheng facilitated a comprehensive discussion with Drs. Sanjoy Dutta, Jeremy Pettus, Jessica Melin, Karin Lange and Renuka Dias. Through role-played scenarios, the speakers explored the T1D care journey from screening and diagnosis to monitoring and management, highlighting the real-world disease burden and the critical importance of early detection. The panel also reviewed current technologies and key decision points that enable effective T1D care.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.

Learn why early detection of T1D in adults matters, why T1D is often missed in dysglycemic adults, its misclassification as T2D, and how islet autoantibody testing supports accurate diagnosis, staging, and timely management. 

Learn why early detection of T1D in children matters, how it reduces DKA risk and supports timely intervention. 

The video discusses the management of patient anxiety after positive T1D islet autoantibody results: Guidance on monitoring, education, and psychosocial support.